Ambry Genetics, Clovis to develop custom assays
June 2019—Ambry Genetics announced a laboratory services agreement with Clovis Oncology.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Indivumed partners with Flagship Biosciences
June 2019—Indivumed and Flagship Biosciences have announced a partnership in which the companies will offer a comprehensive set of services combining Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.
Group K Diagnostics, CDC collaborate
June 2019—Group K Diagnostics has signed an agreement with the Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay for the detection of the Zika virus RNA that can be performed by clinical personnel or health care practitioners where real-time RT-PCR instrumentation is not available.
FDA clears GenMark Dx BCID panel
June 2019—GenMark Diagnostics received FDA 510(k) clearance for its ePlex Blood Culture Identification Gram-Negative Panel.
PerkinElmer introduces DNA test
June 2019—PerkinElmer, in collaboration with Helix, launched a genetic screening test called GenePrism: Actionable Insights, which analyzes a subset of 59 medically actionable genes, including BRCA1 and BRCA2, identified by the American College of Medical Genetics and Genomics.
NeuMoDx, Qiagen expand assay menu
June 2019—Qiagen and NeuMoDx Molecular are expanding the menu for the NeuMoDx 96 and 288 molecular systems. The companies also announced the commercial availability of the NeuMoDx 96 mid-throughput version of the fully integrated PCR-based systems.
GenePOC Carba test obtains CE mark
June 2019—GenePOC announced that its GenePOC Carba assay received CE marking. The assay is a qualitative, in vitro diagnostic test designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with carbapenem nonsusceptibility.
BD FacsDuet system gains CE-IVD certification
May 2019—BD announced CE-IVD certification for its BD FacsDuet automated flow cytometry system. The fully automated sample preparation instrument aims to reduce errors and limit the manual user interactions required to run assays on the BD FacsLyric clinical flow cytometer.
Ipatasertib combo shows promising anti-tumor activity
May 2019—Roche presented at the American Association for Cancer Research annual meeting the initial results from a phase one-b study evaluating the efficacy and safety for the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) as a first-line treatment option for people with advanced triple-negative breast cancer.
FDA approves Tecentriq plus chemo for ES-SCLC
May 2019—Genentech announced FDA approval of Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the initial treatment of adults with extensive-stage small cell lung cancer.